Home > Insider Trading > Filing (0001209191-21-051443)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1087294	Cumberland Pharmaceuticals Inc	CPIX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1695580	Kenneth Krogulski	2525 West End Avenue Suite 950 Nashville TN 37203		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-07-01	85	$2.91	172,085	No	4	P	Direct
Common Stock	Acquisiton	2021-07-02	85	$2.94	172,170	No	4	P	Direct
Common Stock	Acquisiton	2021-07-06	85	$3.14	172,255	No	4	P	Direct
Common Stock	Acquisiton	2021-07-07	85	$3.19	172,340	No	4	P	Direct
Common Stock	Acquisiton	2021-07-08	85	$3.18	172,425	No	4	P	Direct
Common Stock	Acquisiton	2021-07-09	85	$3.13	172,510	No	4	P	Direct
Common Stock	Acquisiton	2021-07-12	85	$3.33	172,595	No	4	P	Direct
Common Stock	Acquisiton	2021-07-13	85	$3.48	172,680	No	4	P	Direct
Common Stock	Acquisiton	2021-07-14	85	$3.33	172,765	No	4	P	Direct
Common Stock	Acquisiton	2021-07-15	85	$3.27	172,850	No	4	P	Direct
Common Stock	Acquisiton	2021-07-16	85	$3.28	172,935	No	4	P	Direct
Common Stock	Acquisiton	2021-07-19	85	$3.23	173,020	No	4	P	Direct
Common Stock	Acquisiton	2021-07-20	85	$3.24	173,105	No	4	P	Direct
Common Stock	Acquisiton	2021-07-21	85	$3.26	173,190	No	4	P	Direct
Common Stock	Acquisiton	2021-07-22	85	$3.36	173,275	No	4	P	Direct
Common Stock	Acquisiton	2021-07-23	85	$3.35	173,360	No	4	P	Direct
Common Stock	Acquisiton	2021-07-26	85	$3.39	173,445	No	4	P	Direct
Common Stock	Acquisiton	2021-07-27	85	$3.39	173,530	No	4	P	Direct
Common Stock	Acquisiton	2021-07-28	85	$3.42	173,615	No	4	P	Direct
Common Stock	Acquisiton	2021-07-29	85	$3.42	173,700	No	4	P	Direct
Common Stock	Acquisiton	2021-07-30	85	$3.31	173,785	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct

Footnotes

The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021.